Ipamorelin Side Effects: Safety Profile, Risks & What to Expect (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Side Effects
Ipamorelin is generally well-tolerated, with most users experiencing minimal adverse effects.
Common (typically mild and transient):
Injection site reactions (redness, itching, minor swelling)
Headache, particularly during initial use
Flushing or warmth sensation post-injection
Mild water retention
Increased hunger in some individuals
Drowsiness, especially with evening doses
Less Common:
Lightheadedness or dizziness
Numbness or tingling in extremities
Joint stiffness
Rare/Theoretical Concerns:
Potential effects on glucose metabolism with long-term use
Theoretical concerns regarding growth promotion in undiagnosed malignancies (applies to all GH-elevating compounds)
Most side effects diminish with continued use as the body adjusts. Starting with lower doses and gradually increasing can minimize initial discomfort.
Frequently Asked Questions
While some users employ extended protocols, cycling (12-16 weeks on, 4-8 weeks off) is generally recommended to maintain receptor sensitivity and pituitary responsiveness. Long-term safety data in humans is limited.
They work differently. Ipamorelin stimulates natural GH production, maintaining physiological pulsatility, while exogenous HGH provides direct hormone replacement. Ipamorelin is generally considered safer with fewer side effects but produces more modest elevations.
There is no direct evidence linking ipamorelin to cancer development. However, growth hormone and IGF-1 can theoretically promote growth of existing malignancies, so individuals with active cancer or high cancer risk should avoid GH-elevating compounds.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561.
Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66.
Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231.
Ghigo E, et al. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
World Anti-Doping Agency. Prohibited List.
Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
U.S. Food and Drug Administration.
Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine. 2008;149(9):601-611.